The accord will use drug delivery technology developed by the US contract manufacturing organisation (CMO) on drugs being developed by Endotis, beginning with preclinical development of its candidate anticoagulant EP37151.
The firms hope to begin Phase I clinical trials of the drug in Q2 next year and anticipate that the collaboration will be extended to other drugs in Endotis’ pipeline.
Tom Stuart, president of Catalent’s oral technologies segment, said: "This collaboration with Endotis, based upon a unique combination of complementary expertise, has been providing exciting results, proving that the various technical hurdles associated with the oral delivery of small-glycol drugs can be overcome.”
